Biomarin Pharmaceutical (BMRN)

Add to Watchlists
Create an Alert
127.19 +0.31  +0.24% NASDAQ May 22, 8:00PM Delayed 2m USD

Biomarin Pharmaceutical Research and Development Expense (Quarterly):

142.07M for March 31, 2015

View 4,000+ financial data types

View Full Chart

Biomarin Pharmaceutical Research and Development Expense (Quarterly) Chart

Export Data
Save Image

Biomarin Pharmaceutical Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 1999. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2015 142.07M
Dec. 31, 2014 141.99M
Sept. 30, 2014 125.69M
June 30, 2014 107.70M
March 31, 2014 86.17M
Dec. 31, 2013 97.31M
Sept. 30, 2013 88.06M
June 30, 2013 85.66M
March 31, 2013 83.74M
Dec. 31, 2012 84.36M
Sept. 30, 2012 66.21M
June 30, 2012 77.81M
March 31, 2012 73.83M
Dec. 31, 2011 57.91M
Sept. 30, 2011 58.58M
June 30, 2011 52.91M
March 31, 2011 45.02M
Dec. 31, 2010 42.20M
Sept. 30, 2010 39.37M
June 30, 2010 35.65M
March 31, 2010 30.10M
Dec. 31, 2009 27.44M
Sept. 30, 2009 26.99M
June 30, 2009 26.32M
March 31, 2009 34.36M
   
Dec. 31, 2008 25.73M
Sept. 30, 2008 26.18M
June 30, 2008 23.76M
March 31, 2008 17.63M
Dec. 31, 2007 24.02M
Sept. 30, 2007 17.24M
June 30, 2007 19.19M
March 31, 2007 18.16M
Dec. 31, 2006 20.57M
Sept. 30, 2006 18.10M
June 30, 2006 15.78M
March 31, 2006 12.28M
Dec. 31, 2005 12.68M
Sept. 30, 2005 13.89M
June 30, 2005 14.82M
March 31, 2005 14.99M
Dec. 31, 2004 12.11M
Sept. 30, 2004 11.81M
June 30, 2004 12.29M
March 31, 2004 13.70M
Dec. 31, 2003 17.59M
Sept. 30, 2003 14.50M
June 30, 2003 11.73M
March 31, 2003 10.99M
Dec. 31, 2002 -13.94M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More

Advertisement

BMRN Research and Development Expense (Quarterly) Benchmarks

Companies
PTC Therapeutics 27.94M
Sarepta Therapeutics 39.16M
Biogen 460.55M

BMRN Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 35.65M Jun 2010
Maximum 142.07M Mar 2015
Average 79.61M

BMRN Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("BMRN", "r_and_d_expense")
  • Last 5 data points: =YCS("BMRN", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.